Leerink Partnrs Has Positive Outlook of LLY FY2026 Earnings

Eli Lilly and Company (NYSE:LLY) – Analysts at Leerink Partnrs lifted their FY2026 earnings estimates for shares of Eli Lilly and Company in a report released on Monday, November 10th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings per share of $32.76 for the year, up from their prior forecast of $31.65. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $23.48 per share. Leerink Partnrs also issued estimates for Eli Lilly and Company’s FY2028 earnings at $48.09 EPS and FY2029 earnings at $54.00 EPS.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period last year, the company posted $1.18 EPS. The business’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS.

Other equities research analysts also recently issued reports about the company. Loop Capital set a $950.00 target price on Eli Lilly and Company in a report on Monday. UBS Group boosted their price objective on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the stock a “buy” rating in a report on Friday. Leerink Partners upgraded Eli Lilly and Company from a “market perform” rating to an “outperform” rating and raised their target price for the company from $886.00 to $1,104.00 in a research note on Monday. Cantor Fitzgerald boosted their price target on Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Finally, DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $981.89.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $965.68 on Tuesday. The stock’s 50-day moving average is $804.63 and its 200-day moving average is $775.74. The company has a market cap of $912.94 billion, a price-to-earnings ratio of 63.12, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $981.99. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors have recently made changes to their positions in the stock. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company during the 1st quarter valued at about $27,000. Sumitomo Mitsui Financial Group Inc. acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at approximately $27,000. Evolution Wealth Management Inc. acquired a new position in Eli Lilly and Company during the 2nd quarter worth $29,000. Steph & Co. grew its stake in shares of Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after purchasing an additional 29 shares in the last quarter. Finally, Financial Gravity Companies Inc. acquired a new position in shares of Eli Lilly and Company during the second quarter valued at $31,000. 82.53% of the stock is owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.